These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6293765)

  • 41. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.
    Schulman SL; Kaiser BA; Polinsky MS; Srinivasan R; Baluarte HJ
    J Pediatr; 1988 Dec; 113(6):996-1001. PubMed ID: 3193322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of childhood steroid-resistant nephrotic syndrome with pulse methylprednisolone and cyclophosphamide.
    Sa GA; Luis JP; Mendonca E; Almeida M; Rosa FC
    Pediatr Nephrol; 1996 Apr; 10(2):250. PubMed ID: 8703725
    [No Abstract]   [Full Text] [Related]  

  • 43. Alkylating agents and purine analogues in primary glomerulonephritis with nephrotic syndrome.
    Ponticelli C; Passerini P
    Nephrol Dial Transplant; 1991; 6(6):381-8. PubMed ID: 1876280
    [No Abstract]   [Full Text] [Related]  

  • 44. Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis.
    McEnery PT; Strife CF
    Pediatr Clin North Am; 1982 Aug; 29(4):875-94. PubMed ID: 7050865
    [No Abstract]   [Full Text] [Related]  

  • 45. [Indications for immunosuppressive agents in glomerular nephropathies].
    Méry JP; Girard JF
    Ann Med Interne (Paris); 1974 Nov; 125(11):795-802. PubMed ID: 4460826
    [No Abstract]   [Full Text] [Related]  

  • 46. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
    Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ciclosporin in the treatment of nephrosis. Minimal change disease and focal-segmental glomerulosclerosis.
    Meyrier A
    Am J Nephrol; 1989; 9 Suppl 1():65-71. PubMed ID: 2646928
    [No Abstract]   [Full Text] [Related]  

  • 48. Focal sclerosing glomerulonephritis: a kinetic evaluation of hemostasis and the effect of anticoagulant therapy: a controlled study.
    Futrakul P; Poshyachinda M; Mitrakul C
    Clin Nephrol; 1978 Nov; 10(5):180-6. PubMed ID: 729213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Steroid therapy in primary glomerulonephritis.
    Davison AM
    Nephrol Dial Transplant; 1990; 5 Suppl 1():23-8. PubMed ID: 2129454
    [No Abstract]   [Full Text] [Related]  

  • 50. [Therapy of lipoid nephrosis].
    Di Toro R
    Pediatria (Napoli); 1977 Dec; 85(4):525-48. PubMed ID: 613297
    [No Abstract]   [Full Text] [Related]  

  • 51. B cell suppression in primary glomerular disease.
    Rood IM; Hofstra JM; Deegens JK; Wetzels JF
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):166-81. PubMed ID: 24602466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Primary glomerulopathies--therapy using corticosteroids and cytostatics (immunosuppressive agents)].
    Lagrue G; Bariéty J
    Munch Med Wochenschr; 1970 Mar; 112(12):515-22. PubMed ID: 5467836
    [No Abstract]   [Full Text] [Related]  

  • 53. [Immunosuppressive therapy (azathioprine and chlorambucil) in some nephrosic syndromes and in chronic active glomerulonephritis].
    Campanacci L; Castellani A; Gambari PF; Fagiolo U; Romagnoli GF
    Minerva Nefrol; 1969; 16(2):130-56. PubMed ID: 4921663
    [No Abstract]   [Full Text] [Related]  

  • 54. [Treatment with immunosuppressive agents in disseminated lupus erythematosus and in some evolutive nephropathies].
    Purice S; Ghelerter L; Matei I; Brunazian G
    Stud Cercet Med Interna; 1969; 10(2):147-53. PubMed ID: 5344004
    [No Abstract]   [Full Text] [Related]  

  • 55. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood.
    McCauley J; Tzakis AG; Fung JJ; Todo S; Starzl TE
    Lancet; 1990 Mar; 335(8690):674. PubMed ID: 1690326
    [No Abstract]   [Full Text] [Related]  

  • 56. Management of the nephrotic syndrome.
    Linshaw MA; Gruskin AB
    Clin Pediatr (Phila); 1974 Jan; 13(1):45-51. PubMed ID: 4588668
    [No Abstract]   [Full Text] [Related]  

  • 57. Coexistence of idiopathic membranous glomerulonephritis and idiopathic focal segmental glomerulosclerosis.
    Matsuo T; Mori Y; Hashimoto T; Tajima M; Okado T; Tsukamoto Y; Kobayashi Y; Sasaki S
    Clin Nephrol; 2005 Dec; 64(6):490-2. PubMed ID: 16370166
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of primary membranous-proliferative glomerulonephritis].
    Martínez Ara J; Rivero Sánchez M; Miguel Alonso JL; Riñón Aguilar C; Almaraz Jiménez MA; Sanz Guajardo A; Sánchez Sicilia L
    Rev Clin Esp; 1975 Oct; 139(1):61-7. PubMed ID: 1197831
    [No Abstract]   [Full Text] [Related]  

  • 59. Cyclophosphamide in the treatment of focal segmental glomerulosclerosis.
    Martinelli R; Pereira LJ; Silva OM; Okumura AS; Rocha H
    Braz J Med Biol Res; 2004 Sep; 37(9):1365-72. PubMed ID: 15334202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined immunosuppressive therapy in adult glomerulonephritis.
    Ojeda W; Cangiano JL; Campos JA; González RR; Vázquez J; Muxó OR
    Bol Asoc Med P R; 1976 Jun; 68(6):137-40. PubMed ID: 779806
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.